A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Key facts

Study ID

NCT06095115

Run by

Janssen Research & Development, LLC

People needed

684

Starts

2023-10-12

Expected to finish

2027-04-06

Last updated by the study team

2026-07-06

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
• Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
• Total psoriasis area and severity index (PASI) >=12 at screening and baseline
• Total investigator global assessment (IGA) >=3 at screening and baseline
• Candidate for phototherapy or systemic treatment for plaque psoriasis
• A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test beta-human chorionic gonadotropin (beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention

You may not qualify if…

• Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
• Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
• A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
• Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
• Major surgical procedures, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from a surgical procedure or has a surgical procedure planned during the time the participant is expected to participate in the study

Where it is running

• Charite - Campus Mitte — Berlin, Germany
• Medical Dermatology Specialists — Phoenix, Arizona, United States
• Johnson Dermatology — Fort Smith, Arkansas, United States
• First OC Dermatology — Fountain Valley, California, United States
• Center for Dermatology Clinical Research — Fremont, California, United States
• Integrative Skin Science and Research — Sacramento, California, United States
• Rady Childrens Hospital San Diego — San Diego, California, United States
• Southern California Dermatology — Santa Ana, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• Bioclinical Research Alliance Inc. — Miami, Florida, United States
• Ziaderm Research LLC — North Miami Beach, Florida, United States
• Forcare Clinical Research Inc — Tampa, Florida, United States
• Skin Care Physicians of Georgia — Macon, Georgia, United States
• Arlington Dermatology — Rolling Meadows, Illinois, United States
• Endeavor Health — Skokie, Illinois, United States
• Dundee Dermatology — West Dundee, Illinois, United States
• Dawes Fretzin Clinical Research Group LLC — Indianapolis, Indiana, United States
• Indiana Clinical Trial Center — Plainfield, Indiana, United States
• Qualmedica Research — Owensboro, Kentucky, United States
• Dermatology and Advanced Aesthetics — Lake Charles, Louisiana, United States
• Allcutis Research 1 — Beverly, Massachusetts, United States
• Michigan Center of Medical Research — Clarkston, Michigan, United States
• Minnesota Clinical Study Center — New Brighton, Minnesota, United States
• Skin Specialists — Omaha, Nebraska, United States
• Hosp Clinic de Barcelona — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.